Gensia Pharmaceuticals Inc. on Tuesday said it had received anotice of allowance on a U.S. patent application for itsexercise simulating agent (ESA) technology.
The patent, one of several the San Diego company is seekingfor ESA, includes the use of closed-loop administration ofcatecholamine compounds for diagnosis and evaluation ofcoronary artery disease. ESA is used to increase the heart ratein patients who cannot exercise, enabling the use ofelectrocardiography, echocardiography and other tests.
Gensia (NASDAQ:GNSA) said the patent might issue in four tosix months.
(c) 1997 American Health Consultants. All rights reserved.